On Friday, Zevra Therapeutics Inc (NASDAQ: ZVRA) opened lower -10.55% from the last session, before settling in for the closing price of $7.39. Price fluctuations for ZVRA have ranged from $3.89 to $8.44 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 44.97%. Company’s average yearly earnings per share was noted -22.31% at the time writing. With a float of $41.52 million, this company’s outstanding shares have now reached $41.53 million.
Let’s determine the extent of company efficiency that accounts for 69 employees.
Zevra Therapeutics Inc (ZVRA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zevra Therapeutics Inc is 0.79%, while institutional ownership is 34.09%. The most recent insider transaction that took place on Jul 17 ’24, was worth 13,540. In this transaction CFO & Treasurer of this company bought 2,000 shares at a rate of $6.77, taking the stock ownership to the 18,469 shares. Before that another transaction happened on Jul 16 ’24, when Company’s Director bought 10,000 for $6.81, making the entire transaction worth $68,065. This insider now owns 20,000 shares in total.
Zevra Therapeutics Inc (ZVRA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -22.31% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Check out the current performance indicators for Zevra Therapeutics Inc (ZVRA). In the past quarter, the stock posted a quick ratio of 2.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.35, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Looking closely at Zevra Therapeutics Inc (NASDAQ: ZVRA), its last 5-days average volume was 3.02 million, which is a jump from its year-to-date volume of 0.4 million. As of the previous 9 days, the stock’s Stochastic %D was 54.52%. Additionally, its Average True Range was 0.63.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 56.84%, which indicates a significant increase from 38.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 139.21% in the past 14 days, which was higher than the 76.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.44, while its 200-day Moving Average is $5.34. However, in the short run, Zevra Therapeutics Inc’s stock first resistance to watch stands at $7.01. Second resistance stands at $7.40. The third major resistance level sits at $7.66. If the price goes on to break the first support level at $6.36, it is likely to go to the next support level at $6.10. Now, if the price goes above the second support level, the third support stands at $5.71.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
There are currently 41,853K shares outstanding in the company with a market cap of 276.63 million. Presently, the company’s annual sales total 27,460 K according to its annual income of -46,050 K. Last quarter, the company’s sales amounted to 3,430 K and its income totaled -16,620 K.
